சுருக்கம்

Clinical therapeutic effects of hepatic arterial chemoembolization combined with cetuximab on patients with colorectal liver metastases

Xue Wu-rong, Zhang Chi, Gao Er-xiang, Wang Ya-ru

Objective: To discuss clinical therapeutic effects of hepatic arterial chemoembolization combined with cetuximab on patients with colorectal liver metastases.

Methods: 50 patients with colorectal liver metastases admitted by our hospital from February 2010 to February 2012 were selected and divided into observation group and control group with 25 patients in each by random lottery. Hepatic arterial chemoembolization was given to patients in control group, and cetuximab was used based on it for patients in observation group. After treatment, clinical therapeutic effects, life quality and adverse effects of patients were compared between two groups. Three years of follow-up was conducted for patients in two groups, and survival rate was analyzed.

Results: After treatment, the effective rate of observation group was 88%, significantly higher than 64% for control group. Carcino-Embryonic Antigen (CEA) (18.53 ± 3.04) μg/L, CA242 (31.24 ± 2.85) IU/ml and CA19-1 (34.68 ± 3.06) KU/ml for patients in observation group were significantly lower than CEA (33.27 ± 4.23) μg/L, CA242 (53.13 ± 4.87) IU/ml and CA19-1 (62.35 ± 6.73) KU/ml in control group, while the life quality and survival rate of observation group were significantly higher than those of control group with statistical significance (P<0.05). The incidence rate of adverse effects, including acneiform rash of patients in observation was 80%, significantly higher than 4% in control group with statistical significance (P<0.05), while the incurrence rate of adverse effects, including nausea and vomiting and diarrhea had no statistical significance (P>0.05).

Conclusion: The therapeutic effects of hepatic arterial chemoembolization combined with cetuximab on patients with colorectal liver metastases were definite that it is worth to be promoted with effective improvement of life quality and survival rate.